Encapsulation of drugs within liposomes by pH-gradient techniques

Liposome Technology: Third Edition

Volumn 2, Issue , 2016, Pages 27-50

  Fenske, David B ^a   Cullis, Pieter R ^b  

^a UNIVERSITY OF THE FRASER VALLEY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052170818     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818.
2. Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol 2005; 391: 7.
3. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283.
4. Liu M, Kono K, Frechet JM. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release 2000; 65: 121.
5. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21: 1184.
6. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238.
7. Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis PR. Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 1986; 40: 89.
8. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979; 557: 9.
9. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985; 812: 55.
10. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858: 161.
11. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 1993; 33: 17.
12. Mayer LD, Tai LC, Ko DS, et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989; 49: 5922.
13. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelincholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896.
14. Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 1998; 42: 461.
15. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994; 54: 2830.
16. Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J Drug Target 1994; 2: 397.
17. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949.
18. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991; 1066: 29.
19. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994; 15: 215.
20. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998; 56: 747.
21. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 1986; 857: 123.
22. Madden TD, Harrigan PR, Tai LC, et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 1990; 53: 37.
23. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1997; 1331: 187.
24. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990; 53: 183.
25. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990; 50: 575.
26. Mayer LD, Bally MB, Cullis PR. Strategies for optimizing liposomal doxorubicin. J Liposome Res 1990; 1: 463.
27. Chonn A, Cullis PR. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995; 6: 698.
28. Cheung TW, Remick SC, Azarnia N, Proper JA, Barrueco JR, Dezube BJ. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin Cancer Res 1999; 5: 3432.
29. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001; 3: 156.
30. Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999; 10: 1113.
31. Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001; 81: 206.
32. Shields AF, Lange LM, Zalupski MM. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. Am J Clin Oncol 2001; 24: 96.
33. Gokhale PC, Radhakrishnan B, Husain SR, et al. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br J Cancer 1996; 74: 43.
34. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 1997; 53: 520.
35. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093.
36. Grunaug M, Bogner JR, Loch O, Goebel FD. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. Eur J Med Res 1998; 3: 13.
37. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37: 870.
38. Israel VP, Garcia AA, Roman L, et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000; 78: 143.
39. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16: 2445.
40. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17: 697.
41. Millar JL, Millar BC, Powles RL, et al. Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice. Br J Haematol 1998; 102: 718.
42. Tokudome Y, Oku N, Doi K, Namba Y, Okada S. Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta 1996; 1279: 70.
43. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 1997; 281: 566.
44. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 1997; 75: 169.
45. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 1999; 17: 775.
46. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 2000; 292: 337.
47. Gill PS, Wernz J, Scadden DT, Cohen P, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353.
48. Pratt G, Wiles ME, Rawstron AC, et al. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma. Hematol Oncol 1998; 16: 47.
49. Webb MS, Boman NL, Wiseman DJ, et al. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother 1998; 42: 45.
50. Bakker-Woudenberg IA, ten Kate MT, Guo L, Working P, Mouton JW. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 2001; 45: 1487.
51. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000; 60: 3389.
52. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95.
53. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408.
54. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993; 1152: 253.
55. Bally MB, Mayer LD, Loughrey H, et al. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 1988; 47: 97.
56. Hope MJ, Wong KF. Liposomal formulation of ciprofloxacin. In: Shek PN, ed. Liposomes in Biomedical Applications. Harwood Academic Publishers, 1995: 121.
57. Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta 1999; 1416: 1.
58. Fenske DB, Wong KF, Maurer E, et al. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta 1998; 1414: 188.
59. Cullis PR. Liposomes by accident. J Liposome Res 2000; 10: ix.
60. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 1973; 298: 1015.
61. Huang C. Studies on phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry 1969; 8: 344.
62. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833.
63. Szoka FJ, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1978; 75: 4194.
64. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925; 66: 375.
65. Fenske DB, Maurer N, Cullis PR. Encapsulation of weakly-basic drugs, antisense oligonucleotides and plasmid DNA within large unilamellar vesicles for drug delivery applications. In: Torchilin VP, Weissig V, eds. Liposomes: A Practical Approach. 2nd ed. Oxford: Oxford University Press, 2002, Chapter 6.
66. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ, Cullis PR. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1993; 1149: 329.
67. Lasic DD, Ceh B, Stuart MC, Guo L, Frederik PM, Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995; 1239: 145.
68. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992; 312: 255.
69. Li X, Hirsh DJ, Cabral-Lilly D, et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998; 1415: 23.
70. Li X, Cabral-Lilly D, Janoff AS, Perkins WR. Complexation of internalized doxorubicin into fiber bundles affects its release rate from liposomes. J Liposome Res 2000; 10: 15.
71. Cheung BCL, Sun THT, Leenhouts JM, Cullis PR. Loading of doxorubicin into liposomes by forming Mn2þ-drug complexes. Biochim Biophys Acta 1998; 1414: 205.
72. Abraham SA, Edwards K, Karlsson G, et al. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 2002; 1565: 41.
73. Abraham SA, McKenzie C, Masin D, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004; 10: 728.
74. Chiu GN, Abraham SA, Ickenstein LM, et al. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release 2005; 104: 271.
75. Rottenberg H. The measurement of membrane potential and delta pH in cells, organelles, and vesicles. Methods Enzymol 1979; 55: 547.
76. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201.
77. Maurer N, Wong KF, Hope MJ, Cullis PR. Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. Biochim Biophys Acta 1998; 1374: 9.
78. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911.
79. 2+into large unilamellar vesicles in response to transmembrane pH gradients. Mol Membr Biol 1994; 11: 151.
80. Zhigaltsev IV, Maurer N, Akhong QF, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 2005; 104: 103.
81. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 2004; 96: 449.